Back to All

Diaceutics Appoints Julie Goonewardene Chair of its Advisory Board

1 December, 2013

Diaceutics, a leading international consulting, software and service solutions company, which helps the pharmaceutical and diagnostic industries understand how to make the personalized medicine business model work for all stakeholders, has appointed Julie Goonewardene as Chairwoman of its Board of Advisors

Ms. Goonewardene is currently President of KUIC and Associate Vice Chancellor for Innovation and Entrepreneurship University of Kansas, and has a track record as an experienced entrepreneur, having co-founded and served as president and CEO of Cantilever Technologies, a venture-backed software company that was successfully acquired. Cantilever’s customers were Fortune 500 companies. Prior to Cantilever, she was president of the Strategic Systems Group (SSG), a boutique information technology consulting firm, and co-founder of Technology Solutions (TSC), a professional IT services firm which went public three years after its inception.

“I am personally delighted to have Julie come on board to help us navigate these important next few years,” said Peter Keeling, Chief Executive Officer of Diaceutics. “Like the personalized medicine business area, Diaceutics itself is undergoing tremendous transformation and growth and Julie’s experience with fast moving technology and companies in the healthcare arena is critical to our next stage of development.”

In addition to her role at KU, Ms. Goonewardene is an author, frequent speaker and consultant on entrepreneurship and innovation. Based on success in these areas, Julie was elected to the Board of Trustees for the American Medical Association (AMA), the Board of Directors of the Personalized Medicine Coalition and Matrix-Bio. As a first generation American born to Sri Lankan and Australian parents, she brings a unique global perspective to her endeavours.

Meeting the needs of personalized medicine is a significant challenge for many in the pharmaceutical and diagnostic industries. Diaceutics is building on its eight years of pioneering leadership in the area to expand its innovative services to this client base, recently adding a laboratory services arm and communications and branding services in partnership with Omnicom.

“Diaceutics is a company in the right place at the right time and I am delighted to help the management team manage this crucial next stage of corporate development,” said Ms. Goonewardene.

Julie takes over from Tiffany Olson, the company’s outgoing chairwoman who has resigned to focus on her new role as President, Nuclear Pharmacy Solutions at Cardinal Health.   “We appreciate the invaluable advice and guidance provided by Tiffany  Over the past two years and wish her well in her new role at Cardinal Health,” said Keeling.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny